Literature DB >> 17269846

Prevalence of drug-related problems and cost-savings opportunities in medicaid high utilizers identified by a pharmacist-run drug regimen review center.

Joanne LaFleur1, Carrieann McBeth, Karen Gunning, Lynda Oderda, Carin Steinvoort, Gary M Oderda.   

Abstract

BACKGROUND: Despite numerous reports of state Medicaid drug utilization review (DUR) programs, little data are available about the prevalence of drugrelated problems (DRPs) in Medicaid patients. A university-based, pharmacist-run DUR program for high utilizers was created as an alternative to imposition of a statutory limit of 7 medications per month in the Utah Medicaid program in 2002. The DUR program was designed to suggest ways that high-utilizing patients could decrease their total number of medications to 7 or fewer prior to imposition of the 7-medication limit at some time in the future.
OBJECTIVE: To describe the experience in 1 Medicaid DUR program and to report the prevalence of DRPs and cost-saving opportunities (CSOs) among a population of Medicaid recipients who were high utilizers of prescription drugs.
METHODS: DRPs were identified by 5 clinical pharmacists employed by the Drug Regimen Review Center (DRRC) in Salt Lake City. The purpose of the center was to provide drug therapy review services for a select number of Utah Medicaid recipients (200-300 per month) who exceeded a 7-medication limit during the calendar years 2003 and 2004.
RESULTS: Out of 391,890 eligible Medicaid recipients, 242,411 (62%) received at least 1 medication, and 16,958 (4.3%) exceeded the 7-medication limit during the review period. Of those exceeding the limit, the DRRC reviewed a total of 3,706 (21.9%) patients, representing the highest utilizers by volume of medication. The prevalence of DRPs considered clinically important in the review cohort was 79.7% of patients, including therapeutic duplications in 54.6% of patients, dose form optimization in 29.7%, and inappropriate uncoordinated care in 25.3%. The average pharmacy cost per month for patients with at least 1 DRP was 1,081 dollars; by contrast, the average pharmacy cost per month for all other patients receiving at least 1 prescription was 91 dollars.
CONCLUSIONS: Approximately 4% of Medicaid recipients exceeded the 7-medication monthly limit. Among the 22% highest utilizers in this group, 48% of nursing home residents and 87% of ambulatory recipients had at least 1 DRP, or an overall rate of 80% of high-use Medicaid recipients or as much as 3.2% of the Medicaid population.

Entities:  

Mesh:

Year:  2006        PMID: 17269846     DOI: 10.18553/jmcp.2006.12.8.677

Source DB:  PubMed          Journal:  J Manag Care Pharm        ISSN: 1083-4087


  5 in total

Review 1.  Application of drug-related problem (DRP) classification systems: a review of the literature.

Authors:  Benjamin J Basger; Rebekah J Moles; Timothy F Chen
Journal:  Eur J Clin Pharmacol       Date:  2014-05-02       Impact factor: 2.953

2.  Assessment of Drug-Drug Interactions among Renal Failure Patients of Nephrology Ward in a South Indian Tertiary Care Hospital.

Authors:  Mylapuram Rama; Gayathri Viswanathan; Leelavathi D Acharya; R P Attur; P N Reddy; S V Raghavan
Journal:  Indian J Pharm Sci       Date:  2012-01       Impact factor: 0.975

3.  Drug related problems identified by clinical pharmacist at the Internal Medicine Ward in Turkey.

Authors:  Nibal Abunahlah; Anfal Elawaisi; Fatih Mehmet Velibeyoglu; Mesut Sancar
Journal:  Int J Clin Pharm       Date:  2018-01-29

Review 4.  Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs.

Authors:  Nicholas Moore; Charles Pollack; Paul Butkerait
Journal:  Ther Clin Risk Manag       Date:  2015-07-15       Impact factor: 2.423

5.  Evaluation of potential drug- drug interactions among Palestinian hemodialysis patients.

Authors:  Rowa' Al-Ramahi; Afnan R Raddad; Alaa O Rashed; Amneh Bsharat; Dania Abu-Ghazaleh; Eman Yasin; Oraina Shehab
Journal:  BMC Nephrol       Date:  2016-07-26       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.